WO2010084150A1 - Diagnostic method for detecting neurodegenerative diseases - Google Patents
Diagnostic method for detecting neurodegenerative diseases Download PDFInfo
- Publication number
- WO2010084150A1 WO2010084150A1 PCT/EP2010/050681 EP2010050681W WO2010084150A1 WO 2010084150 A1 WO2010084150 A1 WO 2010084150A1 EP 2010050681 W EP2010050681 W EP 2010050681W WO 2010084150 A1 WO2010084150 A1 WO 2010084150A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- nrg
- isoform
- neuregulin
- sample
- neurodegenerative diseases
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/475—Assays involving growth factors
- G01N2333/4756—Neuregulins, i.e. p185erbB2 ligands, glial growth factor, heregulin, ARIA, neu differentiation factor
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
Definitions
- the invention relates to a method for the diagnosis of neurodegenerative diseases in a sample by determining the presence and/or amount of an acidic isoform of neuregulin-1 ⁇ > (NRG-Ki) in body fluids.
- Neuregulins also ARIA, neurogenic differentiation factors, heregulins and DDF
- ARIA neurogenic differentiation factors
- DDF neurogenic differentiation factors
- NRG-1, NRG-2, NRG-3 and NRG-4 Due to alternative splicing and posttranslational modification like proteolytic cleavage, phosphorylation and glycosylation the NRG-family members encode many different soluble and transmembrane isoforms. They have been shown to play important roles e.g. in the development of the nervous system. For example in publication Ozaka M.
- WO 99/18976 describes a method for the treatment and/or prophylaxis of neurological diseases comprising administering a neuregulin, or a fragment or derivative of a neuregulin, or a nucleic acid coding for a neuregulin or a neuregulin fragment or derivative thereof to a patient.
- WO 99/18976 only tests on gene level are performed. Since up to over 100 different molecular protein species can be generated from one single gene by modifications on transcript or/and protein level, the indications in WO 99/18976 are not sufficient to identify the protein species actually relevant to neurological processes.
- WO 98/55611 describes the use of a 15 bp-long neuregulin-response- element in therapeutical processes and screening methods for the identification of active agents.
- PCT/EP01/01424 discloses an acidic neuregulin- ⁇ isoform having an isoelectric point of ⁇ pH 7, particularly from pH 4.3 to pH 5.0 and more particularly from pH 4.5 to pH 4.7. This neuregulin- ⁇ isoform was found in mammalian hippocampal cells and characterized as indicator or target, respectively, for neuronal processes.
- PCT/EP02/08778 discloses further neuregulin- ⁇ isoforms associated with neuronal processes and the use of these isoforms as a target for modulating memory and learning in a mammal.
- NRG-1 ⁇ isoform is transported from mammalian central nervous tissues, e.g. brain into body fluids, e.g. into the CSF in neurodegenerative disorders. Furthermore this isoform might be transported via the blood-brain-barrier into the periphery of the body.
- a subject-matter of the present invention is a method for diagnosing and/or monitoring a neurodegenerative disease or condition like e.g. Alzheimer's disease, Parkinson's disease and stroke-related conditions, comprising determining the presence and/or amount of a NRG-1 ⁇ isoform in a body fluid sample.
- An increased amount of a NRG-1fi> isoform versus a control e.g. a sample derived from a normal/healthy subject may be an indication of a neurodegenerative disease or the susceptiblity of the subject for such a condition.
- the NRG-1 ⁇ isoform preferably has an acidic isoelectric point of about ⁇ pH 7, e.g. of about pH 4 to pH 5. Further the isoform preferably has an apparent molecular weight (SDS-PAGE) of about 25-35 kD, e.g. of about 30-32 kD. This isoform preferably comprises the extracellular domain of human NRG-1 ⁇ .
- the sample may be a mammalian, e.g. human body fluid sample, particularly neuronal fluid, more particularly liquor (cerebrospinal fluid). Further the sample may also be obtained from peripheral body fluids, particularly blood, plasma or serum.
- the diagnostic method preferably comprises detection of the NRG-1 ⁇ isoform by immunological methods, e.g. using anti-neuregulin- ⁇ antibodies. Such methods are well known in the art.
- the method comprises determining molecular weight and/or isoelectric point of this isoform. Therefore, an NRG-1 ⁇ isoform containing sample may be subjected to a procedure, wherein proteins are seperated according to their molecular weight and/or charge.
- the separation procedure may be e.g. gel electrophoresis such as SDS-PAGE or an equivalent method.
- determination may comprise chromatographic separation procedures such as HPLC and/or molecular weight exclusion chromatography.
- a quantitative or semiquantitative determination of a NRG-1 ⁇ isoform e.g. of a single NRG-1 ⁇ isoform as described above is carried out.
- This quantitative or semi- quantitative determination may comprise the use of labelled detection reagents such as neuregulin- ⁇ antibodies and quantitatively or semi- quantitatively determining the amount of label bound to a respective neuregulin- ⁇ form in a sample.
- the method additionally comprises a determination of an internal standard, e.g. a reference protein, which allows quantification of the neuregulin- ⁇ isoform to be determined.
- the reference protein exhibits characteristics, e.g.
- the reference protein may be selected from biological extracts, which contain predetermined amounts of recombinant or native neuregulin- ⁇ , purified or partially purified native neuregulin- ⁇ proteins from biologic material, e.g. 42 kD protein from rat hippocampus cell line HK3, purified recombinant protein, e.g. full-length or truncated neuregulin- ⁇ protein or hybrid protein conatining relevant neuregulin- ⁇ epitopes as a ,,tag" coupled to a suitable carrier.
- biological extracts which contain predetermined amounts of recombinant or native neuregulin- ⁇ , purified or partially purified native neuregulin- ⁇ proteins from biologic material, e.g. 42 kD protein from rat hippocampus cell line HK3, purified recombinant protein, e.g. full-length or truncated neuregulin- ⁇ protein or hybrid protein conatining relevant neuregulin- ⁇ epitopes as a ,,tag
- the method of the invention may comprise a diagnostic procedure, wherein a subject to be tested, e.g. a subject presumed to be suffering from or to be susceptible for a neurodegenerative disease is tested.
- the method of the invention may involve the monitoring of the course of a neurodegenerative disease in a subject, particularly a therapy control.
- the invention relates to the use of a reagent kit, comprising detection reagents for NRG-1 ⁇ , e.g. anti-NRG-1 ⁇ antibodies for the diagnosis of neurodegenerative diseases and conditions, particularly in a method as described above. Further, the present invention shall be explained in more detail by the following Figure and Example.
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The invention relates to a method for the diagnosis of neurodegenerative diseases in a sample by determining the presence and/or amount of an acidic isoform of neuregulin-1β (NRG-1β) in body fluids.
Description
_ "I _
Diagnostic method for detecting neurodegenerative diseases
Description
The invention relates to a method for the diagnosis of neurodegenerative diseases in a sample by determining the presence and/or amount of an acidic isoform of neuregulin-1 β> (NRG-Ki) in body fluids.
Neuregulins (also ARIA, neurogenic differentiation factors, heregulins and DDF) belong to a family of wide-spread and known growth and differentiation factors, comprising the members NRG-1, NRG-2, NRG-3 and NRG-4. Due to alternative splicing and posttranslational modification like proteolytic cleavage, phosphorylation and glycosylation the NRG-family members encode many different soluble and transmembrane isoforms. They have been shown to play important roles e.g. in the development of the nervous system. For example in publication Ozaka M. Et al., Nature 1997, Dec 10-25, 390 (6661):691-4 the inducing influence of neuregulin-β on the expression of the NR2C subunit of the NMDA receptor is described. Also Schillo et al (J Proteom Res 4:900-908, 2005) described that NRG-1 β does play a role in learning and memory and Kastin et al (J Neurochem 88(4): 965-970, 2004) could show that neuregulin-1 β is able to cross the blood-brain-barrier, which is interesting for the therapeutic usage of this isoform.
WO 99/18976 describes a method for the treatment and/or prophylaxis of neurological diseases comprising administering a neuregulin, or a fragment or derivative of a neuregulin, or a nucleic acid coding for a neuregulin or a neuregulin fragment or derivative thereof to a patient. In WO 99/18976 only tests on gene level are performed. Since up to over 100 different molecular protein species can be generated from one single gene by modifications on transcript or/and protein level, the indications in WO 99/18976 are not sufficient to identify the protein species actually relevant to neurological processes.
WO 98/55611 describes the use of a 15 bp-long neuregulin-response- element in therapeutical processes and screening methods for the identification of active agents.
PCT/EP01/01424 discloses an acidic neuregulin-β isoform having an isoelectric point of ≤ pH 7, particularly from pH 4.3 to pH 5.0 and more particularly from pH 4.5 to pH 4.7. This neuregulin-β isoform was found in mammalian hippocampal cells and characterized as indicator or target, respectively, for neuronal processes.
PCT/EP02/08778 discloses further neuregulin-β isoforms associated with neuronal processes and the use of these isoforms as a target for modulating memory and learning in a mammal.
Surprisingly, the present inventor has found that a NRG-1 β isoform is transported from mammalian central nervous tissues, e.g. brain into body fluids, e.g. into the CSF in neurodegenerative disorders. Furthermore this isoform might be transported via the blood-brain-barrier into the periphery of the body.
Therefore, a subject-matter of the present invention is a method for diagnosing and/or monitoring a neurodegenerative disease or condition like e.g. Alzheimer's disease, Parkinson's disease and stroke-related conditions, comprising determining the presence and/or amount of a NRG-1β isoform in a body fluid sample. An increased amount of a NRG-1fi> isoform versus a control, e.g. a sample derived from a normal/healthy subject may be an indication of a neurodegenerative disease or the susceptiblity of the subject for such a condition.
The NRG-1 β isoform preferably has an acidic isoelectric point of about < pH 7, e.g. of about pH 4 to pH 5. Further the isoform preferably has an apparent molecular weight (SDS-PAGE) of about 25-35 kD, e.g. of about 30-32 kD.
This isoform preferably comprises the extracellular domain of human NRG-1 β.
The sample may be a mammalian, e.g. human body fluid sample, particularly neuronal fluid, more particularly liquor (cerebrospinal fluid). Further the sample may also be obtained from peripheral body fluids, particularly blood, plasma or serum.
The diagnostic method preferably comprises detection of the NRG-1β isoform by immunological methods, e.g. using anti-neuregulin-β antibodies. Such methods are well known in the art.
In a preferred embodiment, the method comprises determining molecular weight and/or isoelectric point of this isoform. Therefore, an NRG-1 β isoform containing sample may be subjected to a procedure, wherein proteins are seperated according to their molecular weight and/or charge. The separation procedure may be e.g. gel electrophoresis such as SDS-PAGE or an equivalent method. Alternatively, determination may comprise chromatographic separation procedures such as HPLC and/or molecular weight exclusion chromatography.
In a preferred embodiment of the invention, a quantitative or semiquantitative determination of a NRG-1 β isoform, e.g. of a single NRG-1 β isoform as described above is carried out. This quantitative or semi- quantitative determination may comprise the use of labelled detection reagents such as neuregulin-β antibodies and quantitatively or semi- quantitatively determining the amount of label bound to a respective neuregulin-β form in a sample. In some cases, it is preferred that the method additionally comprises a determination of an internal standard, e.g. a reference protein, which allows quantification of the neuregulin-β isoform to be determined. In a preferred embodiment, the reference protein exhibits characteristics, e.g. a molecular weight, which allows a differentiation from the neuregulin-1 β isoform to be determined, particularly after electrophoretic
- A - separation of the sample. For example, the reference protein may be selected from biological extracts, which contain predetermined amounts of recombinant or native neuregulin-β, purified or partially purified native neuregulin-β proteins from biologic material, e.g. 42 kD protein from rat hippocampus cell line HK3, purified recombinant protein, e.g. full-length or truncated neuregulin-β protein or hybrid protein conatining relevant neuregulin-β epitopes as a ,,tag" coupled to a suitable carrier.
The method of the invention may comprise a diagnostic procedure, wherein a subject to be tested, e.g. a subject presumed to be suffering from or to be susceptible for a neurodegenerative disease is tested. Alternatively, the method of the invention may involve the monitoring of the course of a neurodegenerative disease in a subject, particularly a therapy control.
Furthermore, the invention relates to the use of a reagent kit, comprising detection reagents for NRG-1β, e.g. anti-NRG-1 β antibodies for the diagnosis of neurodegenerative diseases and conditions, particularly in a method as described above. Further, the present invention shall be explained in more detail by the following Figure and Example.
Figure 1 :
NRG-1 β-ECD Western blot from liquor (cerebrospinal fluid) samples obtained from Alzheimer patients (AD patients) and non-Alzheimer patients (age-matched controls).
Example:
Western blot analysis of liquor (cerebrospinal fluid, CSF) from human Alzheimer patients (AD) with anti-neuregulin-β antibodies shows increased levels of an acidic NRG-1 β isoform having a molecular weight of about 32 kD and/or neuregulin-1β degradation products in the CSF of these patients compared to age-matched controls (Fig.1).
Claims
1. A method for diagnosing and/or monitoring a neurodegenerative disease comprising determining the presence and/or amount of a human neuregulin-1β (NRG-1 β) isoform in a body fluid sample.
2. The method of claim 1 , wherein the expression of said NRG-1 β isoform is increased in a body fluid sample of patients with a neurodegenerative disease compared to a control.
3. The method of claim 1 and 2, wherein said NRG-1 β isoform is an acidic NRG-1 β isoform.
4. The method of any one of claims 1 to 3, wherein said NRG-1 β isoform has an isoelectric point of from about pH 4 to 5.
5. The method of any one of claims 1 to 4, wherein said NRG-1 β isoform has an apparent molecular weight (SDS-PAGE) of from about 25-35 kD.
6. The method of any one of claims 1 to 5, wherein the sample is liquor, blood, serum or plasma.
7. The method of any one of claims 1 to 6, wherein determining comprises subjecting the sample to a separation procedure according to its molecular weight and/or charge.
8. The method of claim 7, wherein the separation procedure comprises SDS-PAGE.
9. The method of any of the preceding claims wherein the NRG-1 β isoform is determined immunologically.
10. The method of any one of claims 1 to 9, wherein the neurodegenerative diseases are selected from Alzheimer's disease, Parkinson's disease or stroke-related deficits.
11. Use of a reagent kit comprising anti-neuregulin-β antibodies for the diagnosis of neurodegenerative diseases in a method of any of the preceding claims.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US14675209P | 2009-01-23 | 2009-01-23 | |
| US61/146,752 | 2009-01-23 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2010084150A1 true WO2010084150A1 (en) | 2010-07-29 |
Family
ID=41800467
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/EP2010/050681 Ceased WO2010084150A1 (en) | 2009-01-23 | 2010-01-21 | Diagnostic method for detecting neurodegenerative diseases |
Country Status (1)
| Country | Link |
|---|---|
| WO (1) | WO2010084150A1 (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1998055611A1 (en) | 1997-06-06 | 1998-12-10 | Regents Of The University Of Michigan | Neuregulin response element and uses therefor |
| WO1999018976A1 (en) | 1997-10-14 | 1999-04-22 | Cambridge Neuroscience, Inc. | Therapeutic methods comprising use of a neuregulin |
| WO2003014156A2 (en) * | 2001-08-06 | 2003-02-20 | Proteosys Ag | NEUREGULIN-β ISOFORMS ASSOCIATED WITH NEURONAL PROCESSES |
| WO2004019045A2 (en) * | 2002-08-23 | 2004-03-04 | Proteosys Ag | Method for the diagnosis of alzheimer disease |
-
2010
- 2010-01-21 WO PCT/EP2010/050681 patent/WO2010084150A1/en not_active Ceased
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1998055611A1 (en) | 1997-06-06 | 1998-12-10 | Regents Of The University Of Michigan | Neuregulin response element and uses therefor |
| WO1999018976A1 (en) | 1997-10-14 | 1999-04-22 | Cambridge Neuroscience, Inc. | Therapeutic methods comprising use of a neuregulin |
| WO2003014156A2 (en) * | 2001-08-06 | 2003-02-20 | Proteosys Ag | NEUREGULIN-β ISOFORMS ASSOCIATED WITH NEURONAL PROCESSES |
| WO2004019045A2 (en) * | 2002-08-23 | 2004-03-04 | Proteosys Ag | Method for the diagnosis of alzheimer disease |
Non-Patent Citations (5)
| Title |
|---|
| FALLS D L: "Neuregulins: Functions, forms, and signaling strategies.", EXP CELL RES, vol. 284, no. 1, 10 March 2003 (2003-03-10), pages 14 - 30, XP002573567 * |
| KASTIN ET AL., J NEUROCHEM, vol. 88, no. 4, 2004, pages 965 - 970 |
| OZAKA M. ET AL., NATURE, vol. 390, no. 6661, 10 December 1997 (1997-12-10), pages 691 - 4 |
| PANKONIN M S ET AL: "Differential distribution of neuregulin in human brain and spinal fluid.", BRAIN RES, vol. 1258, 29 December 2008 (2008-12-29), pages 1 - 11, XP002573566 * |
| SCHILLO ET AL., J PROTEOM RES, vol. 4, 2005, pages 900 - 908 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6451547B1 (en) | Process for differential diagnosis of Alzheimer's dementia and device therefor | |
| Ghanbari et al. | Biochemical assay for AD7C‐NTP in urine as an Alzheimer's disease marker | |
| EP2339348B1 (en) | Method for diagnosing neuro-degenerative disease | |
| JP2009501333A (en) | Diagnosis of brain injury related disorders | |
| US20210270847A1 (en) | Protein and peptide biomarkers for traumatic injury to the central nervous system | |
| CA2446886A1 (en) | Method for detecting chronic dementia diseases, and corresponding peptides and detection reagents | |
| DK2444814T3 (en) | Biomarker for mental disorders, including cognitive disorders, and method of using the biomarker for detecting mental disorders, including cognitive disorders | |
| CA2467073A1 (en) | Peptides and method for detecting alzheimer's disease and differentiating alzheimer's disease from other demential diseases | |
| US7682795B2 (en) | Method of diagnosing Alzheimer's Disease | |
| CN105548561B (en) | Diagnostic agent and diagnostic method for alzheimer's disease | |
| KR101809094B1 (en) | Biomarkers for diagnosis of age-related macular degeneration or diabetic retinopathy and diagnostic method using the same | |
| KR102033776B1 (en) | Diagnostic composition of alzheimer's disease severity comprising agents measuring expression level of tau protein and diagnostics method of alzheimer's disease severity using the same | |
| KR100689995B1 (en) | Composition for diagnosing retinal vascular disease containing aldolase and method of diagnosis thereof | |
| US7070945B2 (en) | Process for determining the presence of monomeric brain associated human glutamine synthetase in patients exhibiting mild cognitive impairment | |
| WO2010084150A1 (en) | Diagnostic method for detecting neurodegenerative diseases | |
| WO2004019045A2 (en) | Method for the diagnosis of alzheimer disease | |
| KR20220109803A (en) | Diagnosis of Alzheimer's disease Using Plasma | |
| CA3052636A1 (en) | S100.beta. and isoforms for detection of neurological conditions | |
| AU2002252888A1 (en) | Process for differential diagnosis of alzheimer's dementia and device therefor |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 10700581 Country of ref document: EP Kind code of ref document: A1 |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 10700581 Country of ref document: EP Kind code of ref document: A1 |